| abstract |
FIELD: medicine.SUBSTANCE: invention refers to medicine and molecular biology. Essence of the invention is that for the purpose of detecting antibodies belonging to different classes of immunoglobulins, in blood serum or plasma of patients with COVID-19 or infected with said virus, uses a complex of antigenic recombinant proteins (RBD-SD1 and NTD fragments of spike-protein of SARS-CoV-2 virus, as well as nucleoprotein of SARS-CoV-2 virus, obtained on the basis of artificially synthesized genetic structures in plasmid DHFRControlTemplate, incorporated into strain BL21 (DE3)Target recombinant proteins are sorbed in the pits of the folding polystyrene microplates, based on which the test system is formed, including four sets of reagents for both total and separate determination of IgM-, IgG-, IgA-antibodies to SARS-CoV-2 in laboratory diagnostics and clinical-epidemiological monitoring of COVID-19. Invention can be used for producing test systems for serological diagnosis of COVID-19 in order to assess the humoral immune response in infected individuals and epidemiological characteristics of the infectious process in the population, and in the future – to determine the effectiveness of vaccination and immunotherapy when obtaining and implementing the corresponding therapeutic and preventive preparations against SARS-CoV-2.EFFECT: invention provides complete and comprehensive assessment of the immune response to SARS-CoV-2.10 cl, 5 dwg, 1 tbl, 3 annexes |